title: Outcome of treating advanced neuroendocrine tumours with radiolabelled somatostatin analogues.
abstract: OBJECTIVE
  To evaluate the initial response and outcomes (quality of life and presence of side effects) in patients with advanced neuroendocrine tumours (NET) after treatment with radiolabelled somatostatin analogues: (90)Y-DOTATyr3- octreotide ((90)Y-DOTATOC) and (177)Lu-DOTA-Tyr3- octreotate ((177)Lu-DOTATATE).
  
  
  METHODS
  The study included 5 patients with advanced NET referred to European centres for treatment with (90)Y-DOTATOC and (177)Lu-DOTATATE after lack of response to conventional treatment. The mean age was 45.6 years (29-68 years). Response to therapy was assessed according to: (1) RECIST criteria, as complete response, partial response, stable disease or disease progression, (2) post-treatment survival time and (3) quality of life, using the Karnofsky performance index.
  
  
  RESULTS
  All patients survived for >20 months after treatment; mean survival time was 28 months. At the time of writing, three of the patients are alive after 20, 26 and 37 months. Partial response was observed in one patient, stable disease in three and disease progression in the fifth patient. A good-to-excellent post-treatment quality of life was observed in all patients.
  
  
  CONCLUSIONS
  Therapy with radiolabelled somatostatin analogues showed promising results in patients with advanced NET, with a partial response or disease stabilisation in four of the five patients, who have enjoyed an extended survival period and an improved quality of life.
authors.affiliation: Nuclear Medicine Department and Oncology Department, Virgen de las Nieves University Hospital, Granada, Spain. mangustias.muros.sspa@juntadeandalucia.es
authors.forename: M A
authors.initials: MA
authors.lastname: Muros
authors.forename: M
authors.initials: M
authors.lastname: Varsavsky
authors.forename: P
authors.initials: P
authors.lastname: Iglesias Rozas
authors.forename: J
authors.initials: J
authors.lastname: Valdivia
authors.forename: J R
authors.initials: JR
authors.lastname: Delgado
authors.forename: F
authors.initials: F
authors.lastname: Forrer
authors.forename: L
authors.initials: L
authors.lastname: Bodei
authors.forename: G
authors.initials: G
authors.lastname: Paganelli
mesh_terms: D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D018358:Neuroendocrine Tumors / Q000401:mortality / Q000532:radiotherapy*; D015282:Octreotide / Q000031:analogs & derivatives* / Q000627:therapeutic use; D009942:Organometallic Compounds / Q000627:therapeutic use*; D011788:Quality of Life; D013004:Somatostatin / Q000031:analogs & derivatives; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D009942:Organometallic Compounds; D013004:Somatostatin; C496730:90Y-octreotide, DOTA-Tyr(3)-; C447941:lutetium Lu 177 dotatate; D015282:Octreotide